SLFN12

Summary

SLFN12 (schlafen family member 12, HGNC:25500) is a protein-coding gene on chromosome 17q12, encoding Ribonuclease SLFN12 (Q8IYM2). Ribonuclease which is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway.

Enables RNA nuclease activity and ribosome binding activity. Involved in apoptotic signaling pathway and rRNA catabolic process. Part of cytosol and nucleus.

Source: NCBI Gene 55106 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 91 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_018042

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25500
Approved symbol	SLFN12
Name	schlafen family member 12
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10260
Ensembl gene	ENSG00000172123
Ensembl biotype	protein_coding
OMIM	614955
Entrez	55106

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 12 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000304905, ENST00000394562, ENST00000428476, ENST00000445092, ENST00000447040, ENST00000452764, ENST00000460530, ENST00000479326, ENST00000714244, ENST00000714253, ENST00000714254, ENST00000714255, ENST00000714256, ENST00000714257, ENST00000934488, ENST00000934489, ENST00000961656

RefSeq mRNA: 2 — MANE Select: NM_018042 NM_001289009, NM_018042

CCDS: CCDS11295

Canonical transcript exons

ENST00000304905 — 4 exons

Exon	Start	End
ENSE00001518831	35432188	35432500
ENSE00001775159	35421990	35423068
ENSE00004023352	35410922	35411927
ENSE00004023359	35420274	35420381

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 90.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.3393 / max 88.6392, expressed in 1363 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165368	2.9814	1153
165365	1.3525	780
165363	0.2743	124
165367	0.2178	81
165364	0.1801	66
165362	0.1194	57
165369	0.1087	32
165366	0.1050	28

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	90.61	gold quality
mononuclear cell	CL:0000842	90.41	gold quality
leukocyte	CL:0000738	89.62	gold quality
calcaneal tendon	UBERON:0003701	84.33	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.11	gold quality
granulocyte	CL:0000094	81.91	gold quality
right adrenal gland cortex	UBERON:0035827	81.21	gold quality
stromal cell of endometrium	CL:0002255	80.83	gold quality
right adrenal gland	UBERON:0001233	80.48	gold quality
gall bladder	UBERON:0002110	80.24	gold quality
descending thoracic aorta	UBERON:0002345	79.53	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.54	gold quality
left adrenal gland	UBERON:0001234	78.36	gold quality
spleen	UBERON:0002106	78.06	gold quality
thoracic aorta	UBERON:0001515	77.74	gold quality
left adrenal gland cortex	UBERON:0035825	77.50	gold quality
omental fat pad	UBERON:0010414	77.49	gold quality
ascending aorta	UBERON:0001496	77.48	gold quality
peritoneum	UBERON:0002358	77.40	gold quality
right lobe of thyroid gland	UBERON:0001119	77.02	gold quality
adipose tissue of abdominal region	UBERON:0007808	76.68	gold quality
adrenal gland	UBERON:0002369	76.58	gold quality
upper lobe of left lung	UBERON:0008952	76.55	gold quality
left coronary artery	UBERON:0001626	76.42	gold quality
right lung	UBERON:0002167	76.31	gold quality
tibial nerve	UBERON:0001323	76.24	gold quality
left lobe of thyroid gland	UBERON:0001120	76.23	gold quality
left uterine tube	UBERON:0001303	76.13	gold quality
upper lobe of lung	UBERON:0008948	76.05	gold quality
mucosa of stomach	UBERON:0001199	75.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting SLFN12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-4804-3P	99.65	67.78	866
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-4797-5P	99.39	68.01	1354
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-499A-3P	99.18	69.20	1392
HSA-MIR-499B-3P	99.18	69.27	1391
HSA-MIR-4699-5P	98.99	67.50	1210

Literature-anchored findings (GeneRIF, showing 9)

• Ad-SLFN12 overexpression increased the ratio of the mature E-cadherin protein to its precursor protein (PMID:24768141)
• Vulnerability to antineoplastic phosphodiesterase inhibitors inhibitors has been associated with co-expression of PDE3A and SLFN12 in various tumor types. (PMID:29107068)
• SLFN12 regulates human enterocytic differentiation by a pathway involving SERPB12, the deubiquitylases, and Cdx2. (PMID:30045019)
• Schlafen 12 (SLFN12) is a cytosolic protein that stimulates sucrase-isomaltase (SI) expression. (PMID:30875077)
• HSLFN12’s partner hSerpinB12 may contribute to heterochromatin formation. (PMID:31026779)
• The SLFN12 protein and an apoptosis activation marker were co-localized in syncytiotrophoblast of human placentas, where levels of estrogen-related hormones are high, and dynamic cell turnover by apoptosis is critical for successful implantation and placenta development. (PMID:31420216)
• SLFN12 overexpression reduced MDA-MB-231 mammosphere formation. SLFN12 overexpression decreased ZEB1 and Slug protein despite increased ZEB1 and Slug mRNA . SLFN12 knockdown increased ZEB1 protein. Co-expressing ZEB1 attenuated the SLFN12 effect on E-cadherin mRNA and proliferation. (PMID:31838790)
• Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. (PMID:34272366)
• Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells. (PMID:37165099)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slfn4	ENSMUSG00000000204
mus_musculus	Slfn3	ENSMUSG00000018986
mus_musculus	Slfn2	ENSMUSG00000072620
mus_musculus	Slfn1	ENSMUSG00000078763
rattus_norvegicus	Slfn2	ENSRNOG00000037113
rattus_norvegicus	Slfn1	ENSRNOG00000048053
rattus_norvegicus	Slfn4l1	ENSRNOG00000062983

Paralogs (6): SLFN13 (ENSG00000154760), SLFN5 (ENSG00000166750), SLFNL1 (ENSG00000171790), SLFN11 (ENSG00000172716), SLFN12L (ENSG00000205045), SLFN14 (ENSG00000236320)

Protein

Protein identifiers

Ribonuclease SLFN12 — Q8IYM2 (reviewed: Q8IYM2)

Alternative names: Schlafen family member 12

All UniProt accessions (7): Q8IYM2, A0AAQ5BHP3, A0AAQ5BHR9, A0AAQ5BHT2, A0AAQ5BHT4, C9J4K7, C9JIA1

UniProt curated annotations — full annotation on UniProt →

Function. Ribonuclease which is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling. May play a role in cell differentiation.

Subunit / interactions. Homodimer. Interacts with PDE3A; direct low affinity interaction which is stimulated by binding of 17beta-estradiol/E2 to PDE3A and that positively regulates the ribonuclease activity of SLFN12. Interacts with SERPINB12; as part of a pathway regulating cell differentiation.

Subcellular location. Nucleus. Cytoplasm. Cytosol.

Post-translational modifications. Phosphorylation at Ser-368 and Ser-573 negatively regulates the ribonuclease activity. Dephosphorylation is induced by the interaction with PDE3A and stimulates the rRNA ribonuclease activity.

Similarity. Belongs to the Schlafen family. Subgroup II subfamily.

RefSeq proteins (2): NP_001275938, NP_060512* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007421	Schlafen_AlbA_2_dom	Domain
IPR029684	Schlafen	Family
IPR031450	Poxin-SLFN/SLFN_N	Domain
IPR038461	Schlafen_AlbA_2_dom_sf	Homologous_superfamily
IPR048729	SLFN_GTPase-like	Domain

Pfam: PF04326, PF17057, PF21026

UniProt features (64 total): strand 27, helix 19, mutagenesis site 8, sequence variant 3, modified residue 2, turn 2, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
7LRE	ELECTRON MICROSCOPY	2.76
7LRC	ELECTRON MICROSCOPY	2.97
7EG1	ELECTRON MICROSCOPY	3.2
7EG4	ELECTRON MICROSCOPY	3.2
7LRD	ELECTRON MICROSCOPY	3.22
7EG0	ELECTRON MICROSCOPY	3.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IYM2-F1	82.65	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 368, 573

Mutagenesis-validated functional residues (8):

Position	Phenotype
233	loss of interaction with serpinb2.
368	increased ribonuclease activity; when associated with a-573.
368	decreased ribonuclease activity; when associated with e-573.
573	increased ribonuclease activity; when associated with a-368.
573	decreased ribonuclease activity; when associated with e-368.
200	decreased ribosomal rna ribonuclease activity.
205	decreased ribosomal rna ribonuclease activity.
213	loss of function in the e2-induced apoptotic signaling pathway.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 225 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOMF_RNA_NUCLEASE_ACTIVITY, WALLACE_PROSTATE_CANCER_RACE_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOMF_NUCLEASE_ACTIVITY, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GERY_CEBP_TARGETS, FOSTER_TOLERANT_MACROPHAGE_DN, GOBP_APOPTOTIC_SIGNALING_PATHWAY

GO Biological Process (2): rRNA catabolic process (GO:0016075), apoptotic signaling pathway (GO:0097190)

GO Molecular Function (4): RNA nuclease activity (GO:0004540), hydrolase activity (GO:0016787), ribosome binding (GO:0043022), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
RNA catabolic process	1
rRNA metabolic process	1
apoptotic process	1
signal transduction	1
nuclease activity	1
catalytic activity, acting on RNA	1
catalytic activity	1
ribonucleoprotein complex binding	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

342 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLFN12	PDE3A	Q14432	745
SLFN12	SERPINB12	Q96P63	506
SLFN12	SOWAHC	Q53LP3	485
SLFN12	ZNF471	Q9BX82	458
SLFN12	ZNF667	Q5HYK9	447
SLFN12	SLC19A1	P41440	408
SLFN12	LIPG	Q9Y5X9	400
SLFN12	CTSF	Q9UBX1	398
SLFN12	PFKP	Q01813	396
SLFN12	PERP	Q96FX8	396
SLFN12	ACSL5	Q9ULC5	395
SLFN12	PDE3B	Q13370	391
SLFN12	AKR1B1	P15121	386
SLFN12	CXCL5	P42830	380
SLFN12	GJA1	P17302	374

IntAct

58 interactions, top by confidence:

A	B	Type	Score
PDLIM7	BAG3	psi-mi:“MI:0914”(association)	0.800
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
SDC2	PDPK1	psi-mi:“MI:0914”(association)	0.640
AGT	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
CCK	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
KLKB1	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
LAMP2	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
LMNA	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
SLFN12	LPL	psi-mi:“MI:0915”(physical association)	0.560
RAN	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
TSC1	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
VHL	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
SLFN12	YARS1	psi-mi:“MI:0915”(physical association)	0.560
SPTLC1	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
PACSIN1	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
PRPF40A	SLFN12	psi-mi:“MI:0915”(physical association)	0.560
SLFN12	SPRED1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (8): SLFN12 (Affinity Capture-MS), SLFN12 (Affinity Capture-RNA), SLFN12 (Two-hybrid), SLFN12 (Two-hybrid), SLFN12 (Affinity Capture-MS), SLFN12 (Affinity Capture-MS), JMJD6 (Two-hybrid), SUV39H1 (Two-hybrid)

ESM2 similar proteins: A0A140LIF8, A0JN92, A1Z198, A6H603, B1ARD6, B1ARD8, D9I2F9, D9I2G1, D9I2G3, D9I2G4, D9I2H0, E1BPN0, G1SRW8, O02799, P0C7P3, P52630, Q08AF3, Q0GKD5, Q0P3U3, Q149M9, Q1LXZ7, Q1LZ50, Q2LKU9, Q2LKV5, Q2LKW6, Q32KW9, Q5I0J8, Q5NCI0, Q5RCZ8, Q5RFJ8, Q5SY16, Q5U311, Q60766, Q63035, Q68D06, Q6AYC2, Q6AYF9, Q6IEE8, Q6NXR0, Q7Z7L1

Diamond homologs: A0A7H0DNF0, B1ARD6, P20999, P21000, Q01225, Q01226, Q08AF3, Q5RCZ8, Q68D06, Q6IEE8, Q6J362, Q8CBA2, Q8IYM2, Q8QMP8, Q8V4S4, Q9Z0I6, Q9Z0I7, V9GXG1, B1ARD8, G1SRW8, P0C7P3, Q5U311, Q7Z7L1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Extracellular matrix organization	5	11.3×	6e-04
Hemostasis	5	6.4×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

91 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	77
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3063495	GRCh37/hg19 17q12(chr17:33316754-33890206)x1	Pathogenic

SpliceAI

801 predictions. Top by Δscore:

Variant	Effect	Δscore
17:35413235:A:AC	donor_gain	1.0000
17:35413236:C:CC	donor_gain	1.0000
17:35420382:C:CC	acceptor_gain	1.0000
17:35420383:T:C	acceptor_gain	1.0000
17:35420383:T:TC	acceptor_gain	1.0000
17:35421963:T:A	donor_gain	1.0000
17:35421988:A:C	donor_gain	1.0000
17:35422026:T:TA	donor_gain	1.0000
17:35413255:AT:A	donor_gain	0.9900
17:35413300:T:TA	donor_gain	0.9900
17:35413354:CA:C	acceptor_gain	0.9900
17:35413356:C:CC	acceptor_gain	0.9900
17:35420379:ATT:A	acceptor_gain	0.9900
17:35420380:TT:T	acceptor_gain	0.9900
17:35421939:C:CA	donor_gain	0.9900
17:35421944:C:CT	donor_gain	0.9900
17:35422022:T:A	donor_gain	0.9900
17:35422141:T:TA	donor_gain	0.9900
17:35423064:CTTTT:C	acceptor_gain	0.9900
17:35423069:C:CC	acceptor_gain	0.9900
17:35432901:TTACC:T	donor_loss	0.9900
17:35432902:TA:T	donor_loss	0.9900
17:35432903:A:AC	donor_gain	0.9900
17:35432904:C:CC	donor_gain	0.9900
17:35432904:C:CT	donor_loss	0.9900
17:35432904:CCAG:C	donor_gain	0.9900
17:35411928:C:CC	acceptor_gain	0.9800
17:35411929:T:A	acceptor_loss	0.9800
17:35420377:AAATT:A	acceptor_gain	0.9800
17:35420378:AATT:A	acceptor_gain	0.9800

AlphaMissense

3841 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:35411793:A:G	W428R	0.985
17:35411793:A:T	W428R	0.985
17:35411745:C:G	A444P	0.983
17:35422084:A:C	F315L	0.983
17:35422084:A:T	F315L	0.983
17:35422086:A:G	F315L	0.983
17:35411791:C:A	W428C	0.973
17:35411791:C:G	W428C	0.973
17:35411641:C:A	K478N	0.969
17:35411641:C:G	K478N	0.969
17:35411645:A:G	L477S	0.968
17:35411741:A:G	L445P	0.964
17:35422342:A:C	F229L	0.958
17:35422342:A:T	F229L	0.958
17:35422344:A:G	F229L	0.958
17:35422711:A:C	F106L	0.958
17:35422711:A:T	F106L	0.958
17:35422713:A:G	F106L	0.958
17:35411744:G:T	A444D	0.957
17:35422099:G:C	F310L	0.957
17:35422099:G:T	F310L	0.957
17:35422101:A:G	F310L	0.957
17:35422945:C:A	R28S	0.956
17:35422945:C:G	R28S	0.956
17:35422020:A:G	W337R	0.954
17:35422020:A:T	W337R	0.954
17:35411741:A:T	L445H	0.953
17:35411709:A:C	Y456D	0.946
17:35411792:C:G	W428S	0.946
17:35411738:A:G	L446P	0.945

dbSNP variants (sampled 300 via entrez): RS1000028843 (17:35434724 G>A), RS1000279712 (17:35412528 A>G), RS1000622909 (17:35418953 C>T), RS1000723247 (17:35411214 C>T), RS1001098269 (17:35416648 A>G), RS1001199942 (17:35428246 T>A), RS1001259943 (17:35429364 G>A,T), RS1001307550 (17:35415445 T>C), RS1001308370 (17:35428408 T>C), RS1001443723 (17:35415701 G>A), RS1001603668 (17:35421608 C>G,T), RS1001702574 (17:35433648 C>T), RS1001709137 (17:35427428 G>T), RS1001906339 (17:35432866 A>G), RS1002162056 (17:35425583 A>G)

Disease associations

OMIM: gene MIM:614955 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (1): Non-syndromic anorectal malformation (Orphanet:557)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5291543 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.19	Kd	65	nM	CHEMBL4247714
6.06	Kd	870	nM	CHEMBL4247714

PubChem BioAssay actives

2 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(4R)-3-[4-(diethylamino)-3-nitrophenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one	1952696: Binding affinity to human recombinant SLFN12 expressed as Escherichia coli assessed as dissociation constant	kd	0.0650	uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	6
trichostatin A	increases expression, affects cotreatment	3
sodium arsenite	decreases expression, increases abundance, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Formaldehyde	decreases expression	2
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
Particulate Matter	decreases expression, increases abundance	2
urushiol	decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects cotreatment	1
perfluorooctane sulfonic acid	decreases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
belinostat	increases expression	1
ICG 001	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Cannabidiol	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Vanadates	decreases expression	1
Zinc	decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5256549	Binding	Binding affinity to SLFN12 (unknown origin) assessed as dissociation constant	Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties. — ACS Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D6BK	HyCyte HeLa KO-hSLFN12	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.